FORTEO

This brand name is authorized in United States. It is also authorized in Australia, Brazil, Canada, Hong Kong SAR China, Israel, Japan, New Zealand, Singapore, South Africa.

Active ingredients

The drug FORTEO contains one active pharmaceutical ingredient (API):

1	Teriparatide UNII 10T9CSU89I - TERIPARATIDE
	Teriparatide (rhPTH(1-34)) is the active fragment (1-34) of endogenous human parathyroid hormone. Teriparatide is a bone formation agent to treat osteoporosis. The skeletal effects of teriparatide depend upon the pattern of systemic exposure.
	Read more about Teriparatide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FORTEO Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H05AA02	Teriparatide	H Systemic hormonal preparations, excl. Sex hormones and insulins → H05 Calcium homeostasis → H05A Parathyroid hormones and analogues → H05AA Parathyroid hormones and analogues
Discover more medicines within H05AA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	9411H
BR	Câmara de Regulação do Mercado de Medicamentos	507612110017403
CA	Health Products and Food Branch	02254689
HK	Department of Health Drug Office	59594
IL	מִשְׂרַד הַבְּרִיאוּת	4730
JP	医薬品医療機器総合機構	2439400G1020
NZ	Medicines and Medical Devices Safety Authority	10310
SG	Health Sciences Authority	12593P
US	FDA, National Drug Code	0002-8400
ZA	Health Products Regulatory Authority	36/21.4/0334